Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma

HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative bi...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2024-02, Vol.40, p.101875, Article 101875
Main Authors: Thompson, Eric M, Kang, Kyung-Don, Stevenson, Kevin, Zhang, Hengshan, Gromeier, Matthias, Ashley, David, Brown, Michael, Friedman, Gregory K
Format: Article
Language:English
Subjects:
G207
Medulloblastoma
Oncolytic virus
Original Research
Pediatric high-grade glioma
PVSRIPO
Viral immunotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103
cites cdi_FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103
container_end_page
container_issue
container_start_page 101875
container_title Translational oncology
container_volume 40
creator Thompson, Eric M
Kang, Kyung-Don
Stevenson, Kevin
Zhang, Hengshan
Gromeier, Matthias
Ashley, David
Brown, Michael
Friedman, Gregory K
description HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative biomarkers of response. Multiple pediatric high-grade glioma and medulloblastoma cell lines were treated with various multiplicities of infection of G207 or PVSRIPO. There was a significant inverse correlation between expression of one HSV cellular receptor, CD111, and the lethal dose of 50% of cells (LD50) of cells treated with G207 (r = -0.985, P
doi_str_mv 10.1016/j.tranon.2024.101875
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a1861e1580df46258533f5041fbd02cc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a1861e1580df46258533f5041fbd02cc</doaj_id><sourcerecordid>2915572195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103</originalsourceid><addsrcrecordid>eNpVUstu1TAUjBCIlsIfIOQlm1z8iPNYIVSVtlIlNrC2jh9JfOXYwXYK_D2-pFTtwrI1PmfOeDxV9Z7gA8Gk_XQ85Ag--APFtDlBfcdfVOdkYG3NKWMvn5zPqjcpHTFuyUDp6-qM9aRnPabn1e8rtymrIVs_IWWc2xxEFE1ag08G5YByNJAX4zP6ZfOM7m0Eh-yybD7k2URYrUnIerQabSFHq9Bsp7meImiDJmfDAgi8RovRm3NBOki5YG-rVyO4ZN497BfVj69X3y9v6rtv17eXX-5q1WCe65azpgPVUsBasxGKfjwCLuJlNxigBMpqdae7XjI1tKwbpGwkyLFjRhLMLqrbnVcHOIo12gXiHxHAin9AiJOAmK1yRgDpW2II77Eem5bynjM2ctyQUWpMlSpcn3eudZPlOaqYUsx4Rvr8xttZTOFeENzjgZCuMHx8YIjh52ZSFotNJ9vBm7AlQQfCeUfJwEtps5eqGFKKZnycQ7A4JUAcxZ4AcUqA2BNQ2j481fjY9P_L2V_JXLJZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915572195</pqid></control><display><type>article</type><title>Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma</title><source>ScienceDirect®</source><source>PubMed Central</source><creator>Thompson, Eric M ; Kang, Kyung-Don ; Stevenson, Kevin ; Zhang, Hengshan ; Gromeier, Matthias ; Ashley, David ; Brown, Michael ; Friedman, Gregory K</creator><creatorcontrib>Thompson, Eric M ; Kang, Kyung-Don ; Stevenson, Kevin ; Zhang, Hengshan ; Gromeier, Matthias ; Ashley, David ; Brown, Michael ; Friedman, Gregory K</creatorcontrib><description>HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative biomarkers of response. Multiple pediatric high-grade glioma and medulloblastoma cell lines were treated with various multiplicities of infection of G207 or PVSRIPO. There was a significant inverse correlation between expression of one HSV cellular receptor, CD111, and the lethal dose of 50% of cells (LD50) of cells treated with G207 (r = -0.985, P&lt;0.001) but no correlation between PVSRIPO cellular receptor expression (CD155) and LD50. RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1.  Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.</description><identifier>ISSN: 1936-5233</identifier><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1016/j.tranon.2024.101875</identifier><identifier>PMID: 38183802</identifier><language>eng</language><publisher>United States: Neoplasia Press</publisher><subject>G207 ; Medulloblastoma ; Oncolytic virus ; Original Research ; Pediatric high-grade glioma ; PVSRIPO ; Viral immunotherapy</subject><ispartof>Translational oncology, 2024-02, Vol.40, p.101875, Article 101875</ispartof><rights>Copyright © 2024. Published by Elsevier Inc.</rights><rights>2024 The Authors. Published by Elsevier Inc. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103</citedby><cites>FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103</cites><orcidid>0000-0002-6260-3902 ; 0000-0002-3957-1164 ; 0000-0003-2796-9914 ; 0000-0002-4754-5900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809117/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809117/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38183802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Eric M</creatorcontrib><creatorcontrib>Kang, Kyung-Don</creatorcontrib><creatorcontrib>Stevenson, Kevin</creatorcontrib><creatorcontrib>Zhang, Hengshan</creatorcontrib><creatorcontrib>Gromeier, Matthias</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>Brown, Michael</creatorcontrib><creatorcontrib>Friedman, Gregory K</creatorcontrib><title>Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma</title><title>Translational oncology</title><addtitle>Transl Oncol</addtitle><description>HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative biomarkers of response. Multiple pediatric high-grade glioma and medulloblastoma cell lines were treated with various multiplicities of infection of G207 or PVSRIPO. There was a significant inverse correlation between expression of one HSV cellular receptor, CD111, and the lethal dose of 50% of cells (LD50) of cells treated with G207 (r = -0.985, P&lt;0.001) but no correlation between PVSRIPO cellular receptor expression (CD155) and LD50. RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1.  Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.</description><subject>G207</subject><subject>Medulloblastoma</subject><subject>Oncolytic virus</subject><subject>Original Research</subject><subject>Pediatric high-grade glioma</subject><subject>PVSRIPO</subject><subject>Viral immunotherapy</subject><issn>1936-5233</issn><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUstu1TAUjBCIlsIfIOQlm1z8iPNYIVSVtlIlNrC2jh9JfOXYwXYK_D2-pFTtwrI1PmfOeDxV9Z7gA8Gk_XQ85Ag--APFtDlBfcdfVOdkYG3NKWMvn5zPqjcpHTFuyUDp6-qM9aRnPabn1e8rtymrIVs_IWWc2xxEFE1ag08G5YByNJAX4zP6ZfOM7m0Eh-yybD7k2URYrUnIerQabSFHq9Bsp7meImiDJmfDAgi8RovRm3NBOki5YG-rVyO4ZN497BfVj69X3y9v6rtv17eXX-5q1WCe65azpgPVUsBasxGKfjwCLuJlNxigBMpqdae7XjI1tKwbpGwkyLFjRhLMLqrbnVcHOIo12gXiHxHAin9AiJOAmK1yRgDpW2II77Eem5bynjM2ctyQUWpMlSpcn3eudZPlOaqYUsx4Rvr8xttZTOFeENzjgZCuMHx8YIjh52ZSFotNJ9vBm7AlQQfCeUfJwEtps5eqGFKKZnycQ7A4JUAcxZ4AcUqA2BNQ2j481fjY9P_L2V_JXLJZ</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Thompson, Eric M</creator><creator>Kang, Kyung-Don</creator><creator>Stevenson, Kevin</creator><creator>Zhang, Hengshan</creator><creator>Gromeier, Matthias</creator><creator>Ashley, David</creator><creator>Brown, Michael</creator><creator>Friedman, Gregory K</creator><general>Neoplasia Press</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6260-3902</orcidid><orcidid>https://orcid.org/0000-0002-3957-1164</orcidid><orcidid>https://orcid.org/0000-0003-2796-9914</orcidid><orcidid>https://orcid.org/0000-0002-4754-5900</orcidid></search><sort><creationdate>20240201</creationdate><title>Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma</title><author>Thompson, Eric M ; Kang, Kyung-Don ; Stevenson, Kevin ; Zhang, Hengshan ; Gromeier, Matthias ; Ashley, David ; Brown, Michael ; Friedman, Gregory K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>G207</topic><topic>Medulloblastoma</topic><topic>Oncolytic virus</topic><topic>Original Research</topic><topic>Pediatric high-grade glioma</topic><topic>PVSRIPO</topic><topic>Viral immunotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Eric M</creatorcontrib><creatorcontrib>Kang, Kyung-Don</creatorcontrib><creatorcontrib>Stevenson, Kevin</creatorcontrib><creatorcontrib>Zhang, Hengshan</creatorcontrib><creatorcontrib>Gromeier, Matthias</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>Brown, Michael</creatorcontrib><creatorcontrib>Friedman, Gregory K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Eric M</au><au>Kang, Kyung-Don</au><au>Stevenson, Kevin</au><au>Zhang, Hengshan</au><au>Gromeier, Matthias</au><au>Ashley, David</au><au>Brown, Michael</au><au>Friedman, Gregory K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma</atitle><jtitle>Translational oncology</jtitle><addtitle>Transl Oncol</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>40</volume><spage>101875</spage><pages>101875-</pages><artnum>101875</artnum><issn>1936-5233</issn><eissn>1936-5233</eissn><abstract>HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative biomarkers of response. Multiple pediatric high-grade glioma and medulloblastoma cell lines were treated with various multiplicities of infection of G207 or PVSRIPO. There was a significant inverse correlation between expression of one HSV cellular receptor, CD111, and the lethal dose of 50% of cells (LD50) of cells treated with G207 (r = -0.985, P&lt;0.001) but no correlation between PVSRIPO cellular receptor expression (CD155) and LD50. RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1.  Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.</abstract><cop>United States</cop><pub>Neoplasia Press</pub><pmid>38183802</pmid><doi>10.1016/j.tranon.2024.101875</doi><orcidid>https://orcid.org/0000-0002-6260-3902</orcidid><orcidid>https://orcid.org/0000-0002-3957-1164</orcidid><orcidid>https://orcid.org/0000-0003-2796-9914</orcidid><orcidid>https://orcid.org/0000-0002-4754-5900</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-5233
ispartof Translational oncology, 2024-02, Vol.40, p.101875, Article 101875
issn 1936-5233
1936-5233
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a1861e1580df46258533f5041fbd02cc
source ScienceDirect®; PubMed Central
subjects G207
Medulloblastoma
Oncolytic virus
Original Research
Pediatric high-grade glioma
PVSRIPO
Viral immunotherapy
title Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A03%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elucidating%20cellular%20response%20to%20treatment%20with%20viral%20immunotherapies%20in%20pediatric%20high-grade%20glioma%20and%20medulloblastoma&rft.jtitle=Translational%20oncology&rft.au=Thompson,%20Eric%20M&rft.date=2024-02-01&rft.volume=40&rft.spage=101875&rft.pages=101875-&rft.artnum=101875&rft.issn=1936-5233&rft.eissn=1936-5233&rft_id=info:doi/10.1016/j.tranon.2024.101875&rft_dat=%3Cproquest_doaj_%3E2915572195%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-65347ac62a0dd3fa9220fa0380b79ea21aa216d7d78b3c96379bb4babf73eb103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2915572195&rft_id=info:pmid/38183802&rfr_iscdi=true